- About Us
- Our Programs
- Our Events
- uCity Square
- Support Us
February 14, 2019
PHILADELPHIA--(February 11, 2019) – What if love and kindness could spread like a virus? As part of the University City Science Center’s BioArt Residency, artist Heather Dewey-Hagborg created a custom virus able to increase the production of oxytocin, a hormone that induces feelings of love, kindness, and empathy. The project, titled Lovesick, was developed by Dewey-Hagborg in collaboration with research scientists at the University City Science Center and uCity Square-based biotech company Integral Molecular.
The BioArt Residency program fosters collaboration between artists and scientists within a controlled environment. Not only does it allow both parties to gain new perspectives, but artists are able to serve as intermediaries communicating and creating dialog around complex scientific issues. As part of each residency, the artist spends three months working on creative research projects in Integral Molecular’s laboratories leveraging the guidance and expertise of trained scientists.
The work by Dewey-Hagborg is envisioned as an activist intervention, to spread love and kindness and to combat the alienation and disconnection of the present. Echoing recent debates around genetic editing and the role of ethics in science, Lovesick amplifies the dialog around the possibility of selecting one’s emotions through biotechnology. Although the Lovesick virus has the ability to function in cells in a lab environment, it cannot replicate and will not be used to infect actual animals or people.
“Lovesick plays poetically on the idea of romantic infatuation as a virus, and the process of moving on as building up antibodies. Lovesick examines desire and intimacy in a ubiquitous genomic future where biotechnology is inexpensive and accessible,” says Dewey-Hagborg, who will discuss the project at the February 21 Venture Café Philadelphia Thursday Gathering.
The project involved creating a virus that expresses the hormone oxytocin. Commonly referred to as the “Love Hormone,” oxytocin is associated with feelings of love, bonding, devotion, kindness, and the promotion of empathy, monogamy, and connection. The virus is based on a harmless, non-replicating virus vector that is safely used in hundreds of labs worldwide. After entering a cell and delivering the oxytocin-producing gene, the virus also expresses a fluorescent protein called dsRED that causes the cells to glow bright red.
"Our scientists work hard every day creating new vaccines and therapeutics to help patients, so this collaboration has been an extraordinary opportunity to apply tools in biotechnology that we have used for decades - cells, viruses, and DNA – to art and emotion," said Benjamin Doranz, CEO of Integral Molecular. "We take seriously our responsibility to communicate what we do to the public, and hope that the BioArt residency program and Heather’s project helps explain biotechnology in a different way.”
The BioArt Residency is supported by The John S. and James L. Knight Foundation.
About the Science Center
Located in the heart of uCity Square, the Science Center is a mission-driven nonprofit organization that catalyzes and connects innovation to entrepreneurship and technology commercialization. For 50+ years, the Science Center has supported startups, research, and economic development in the life sciences, healthcare, physical sciences, and emerging technology sectors. As a result, graduate firms and current residents of the Science Center’s incubator support one out of every 100 jobs in the Greater Philadelphia region and drive $13 billion in economic activity in the region annually. By providing resources and programming for any stage of a business’s lifecycle, the Science Center helps scientists, entrepreneurs and innovators take their concepts from idea to IPO – and beyond. For more information about the Science Center, go to www.sciencecenter.org
About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in membrane protein antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic disorders.